Guided Therapeutics (GTHP) Total Debt Growth (1y) (2011 - 2025)
Guided Therapeutics (GTHP) Total Debt Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 157.11% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -12.26% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -1.95% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -2.48% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 0.12% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 19.06% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -5.76% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | -2.49% |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -51.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -51.06% |
| Sep 30, 2025 | -97.55% |
| Jun 30, 2025 | -97.06% |
| Mar 31, 2025 | 70.81% |
| Sep 30, 2024 | 1,156.48% |
| Jun 30, 2024 | 111.19% |
| Mar 31, 2024 | 5.42% |
| Sep 30, 2023 | -91.34% |
| Jun 30, 2023 | 636.31% |
| Mar 31, 2023 | -15.67% |
| Dec 31, 2022 | -89.18% |
| Sep 30, 2022 | 35.03% |
| Jun 30, 2022 | -91.38% |
| Mar 31, 2022 | -95.63% |
| Dec 31, 2021 | 93.18% |
| Sep 30, 2021 | 1,510.00% |
| Jun 30, 2021 | 51.88% |
| Mar 31, 2021 | 7.11% |
| Dec 31, 2020 | -38.14% |
| Sep 30, 2020 | -92.40% |